Cantor Fitzgerald Reiterates Overweight on Mereo BioPharma Group, Maintains $7 Price Target
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Kristen Kluska reiterated an Overweight rating on Mereo BioPharma Group (NASDAQ:MREO) and maintained a $7 price target.
March 22, 2024 | 5:58 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cantor Fitzgerald reaffirmed an Overweight rating on Mereo BioPharma Group with a $7 price target.
The reiteration of an Overweight rating and maintenance of a $7 price target by a reputable analyst firm like Cantor Fitzgerald could instill confidence among investors and potentially drive MREO's stock price up in the short term. Analyst ratings often influence market perceptions and investor decisions, making this reaffirmation significant for MREO's stock.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100